Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma

BACKGROUND: Blinatumomab is a bispecific T-cell engager (BiTE®) antibody construct targeting CD3ε on T cells and CD19 on B cells. We describe the relationship between pharmacokinetics (PK) of blinatumomab and pharmacodynamic (PD) changes in peripheral lymphocytes, serum cytokines, and tumor size in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijazi, Youssef, Klinger, Matthias, Kratzer, Andrea, Wu, Benjamin, Baeuerle, Patrick A., Kufer, Peter, Wolf, Andreas, Nagorsen, Dirk, Zhu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327122/
https://www.ncbi.nlm.nih.gov/pubmed/29773068
http://dx.doi.org/10.2174/1574884713666180518102514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327122/
https://www.ncbi.nlm.nih.gov/pubmed/29773068
http://dx.doi.org/10.2174/1574884713666180518102514

Ejemplares similares